Literature DB >> 398417

Glomerular deposition of complement-control proteins in acute and chronic glomerulonephritis.

R J Wyatt, A J McAdams, J Forristal, J Snyder, C D West.   

Abstract

Acute poststreptococcal glomerulonephritis (AGN) differed from membranoproliferative glomerulonephritis (MPGN) and lupus nephritis (SLE) in that two of the proteins that control the C3b-dependent convertase, beta 1H and the C3bC4b-inactivator cofactor (C3bC4bICo), were frequently absent from the glomerular deposits. In addition, factor B was distributed with C3 in the capillary walls in hypocomplementemic AGN patients. From this, it can be assumed that C3bBb is in the deposits, uninhibited by control proteins as would be predicted for alternative pathway activation. Factor B could not be found in normocomplementemic AGN, was rarely present in MPGN, but was usually present in SLE, most often in the mesangium. In MPGN and SLE, the control proteins were nearly always present in the glomeruli in a distribution like that of C3; IN MPGN they were particularly abundant. Complement profiles indicated an occasional transient reduction in serum C4 level early in AGN. Thus, although there is occasional evidence of early classical activation in AGN, more characteristic is a long period of alternative activation. Serum levels of control proteins did not deviate greatly from normal except for reduced serum beta 1H levels in MPGN type I.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 398417     DOI: 10.1038/ki.1979.156

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

Review 1.  Autoantibodies against C1q: view on clinical relevance and pathogenic role.

Authors:  C E Siegert; M D Kazatchkine; A Sjöholm; R Würzner; M Loos; M R Daha
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

Review 2.  Post-streptococcal acute glomerulonephritis in children: clinical features and pathogenesis.

Authors:  T Matthew Eison; Bettina H Ault; Deborah P Jones; Russell W Chesney; Robert J Wyatt
Journal:  Pediatr Nephrol       Date:  2010-07-23       Impact factor: 3.714

3.  The C1q subunit of the first component of complement binds to laminin: a mechanism for the deposition and retention of immune complexes in basement membrane.

Authors:  J F Bohnsack; A J Tenner; G W Laurie; H K Kleinman; G R Martin; E J Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

4.  Determination of serum bactericidal activity with the aid of luminous bacteria.

Authors:  M Barak; S Ulitzur; D Merzbach
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

5.  The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.

Authors:  Hideharu Sekine; Ting Ting Hsieh Kinser; Fei Qiao; Efrain Martinez; Emily Paulling; Phillip Ruiz; Gary S Gilkeson; Stephen Tomlinson
Journal:  Arthritis Rheum       Date:  2011-04

Review 6.  Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.

Authors:  Tilo Freiwald; Behdad Afzali
Journal:  Adv Immunol       Date:  2021-11-19       Impact factor: 3.543

7.  A new role for complement in experimental membranous nephropathy in rats.

Authors:  D J Salant; S Belok; M P Madaio; W G Couser
Journal:  J Clin Invest       Date:  1980-12       Impact factor: 14.808

8.  Complement profiles in acute post-streptococcal glomerulonephritis.

Authors:  R J Wyatt; J Forristal; C D West; S Sugimoto; J G Curd
Journal:  Pediatr Nephrol       Date:  1988-04       Impact factor: 3.714

9.  A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.

Authors:  F B Waldo; J Forristal; L Beischel; C D West
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

10.  Mast Cells are Important Modifiers of Autoimmune Disease: With so Much Evidence, Why is There Still Controversy?

Authors:  Melissa A Brown; Julianne K Hatfield
Journal:  Front Immunol       Date:  2012-06-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.